71 results about "Lipoproteins Receptors" patented technology

The invention provides a compound of the following formula (1):

wherein m, n, and p are independently an integer of 0-4, provided 3≦m+n≦8; X is nitrogen atom or a group of the formula: C—R¹⁵; Y is a substituted or unsubstituted aromatic group, etc.; R¹⁵, R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc.,

or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.

The invention provides a bionic nanocarrier for treating GBM (glioblastoma) and a preparation method of the bionic nanocarrier and belongs to the field of biomedical engineering. According to the bionic nanocarrier for treating the GBM and the preparation method of the bionic nanocarrier, Ang-RBCm-CA/siRNA comprises Ang-RBCm (Ang (Angiopep-2) polypeptide modified red blood cell membrane) and citraconic anhydride grafted polylysine and polyethylenimine-siRNA compound (CA/siRNA). Ang-RBCm-CA/siRNA can effectively carry siRNA and protect siRNA against degradation. The Ang-RBCm-CA/siRNA has prolonged blood circulation time and high blood brain barrier penetrability, can be efficiently taken in by U87MG brain glial cells over-expressed by a low-density LPR (lipoprotein receptor) and can realizerapid charge conversion in endosome/lysosome, effectively release siRNA and effectively treat in-situ U87MG GBM.

The present invention relates to a compound as shown in a formula (VII), a preparation method and applications thereof in medicines. In particular, the present invention relates to a derivative of the compound as shown in the formula (VII), a preparation method, and the applications of the derivative used as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, II-type diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the present invention can also reduce total cholesterol, LDL-cholesterol and triglyceride, and increases expression of a liver LDL receptor and decreases expression of PCSK9.

Disclosed are a LDL-like cationic nanoparticle for delivering a nucleic acid gene with improved transfection efficiency and stability, which is surface modified and re-constructed by mimicking lipid components of a natural LDL, a method for preparation of the same, and a method for delivering nucleic acid genes using the same. The cationic nanoparticle of the present invention could effectively be applied in treatment of cancer that overexpress LDL receptors.

The invention discloses a dual-mode immunoassay method of an ovarian cancer tumor marker. A sensing interface is constructed by taking a carbon nanohorn and copper nano-cluster functionalized mixed phase (anatase/ rutile) titanium dioxide mesoscopic crystal as a substrate, therefore, a lipolysis activated lipoprotein receptor antibody (Ab) (an early ovarian cancer tumor marker antibody) is immobilized; a free lipolysis activated lipoprotein receptor (an early ovarian cancer tumor marker) can be specifically recognized and combined with the immobilized lipolysis activated lipoprotein receptor antibody to the sensing interface, so as to cause the weakening of a photocurrent signal of an electrode and weaken the capability of the electrode to catalyze and decompose hydrogen peroxide; and hydrogen peroxide solutions with different concentrations can also oxidize and reduce methylene blue so as to enable the methylene blue to present blue with different chromaticities. Based on the phenomenon, a dual-mode analysis method for the colorimetric and photoelectrochemical response of the lipolysis activated lipoprotein receptor can be established.

Provided are a tetrahydroisoquinoline derivative and an application thereof. The invention relates to a compound represented by the formula (V) and a preparation method and an application thereof in medicines. In particular, the invention relates to the derivative of the compound represented by the general formula (V) and a preparation method and the application thereof as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, type-II diabetes, hyperglycemia, obesity or insulin resistance syndromes and metabolic syndromes. The compound disclosed by the invention also can reduce total cholesterol, LDL-cholesterol and triglycerides, and increases the expression of hepatic LDL receptors and inhibits the expression of PCSK9.

The invention discloses a construction method of an atherosclerosis vulnerable plaque mouse model. According to the method, a low-density lipoprotein receptor gene (LDLR) with heterozygous point mutation in a fibrillin-1 (Fbn1) gene is obtained through a hybridization method to knock out a mouse. According to the method, Fbn1C1039G+/- point mutation is introduced into an LDLR-/- mouse genome for the first time, characteristics of two genotypes are combined, the method is simple and easy to implement, and vulnerable plaques with large lipid cores, a large number of inflammatory cells, typical thin fibrous caps, rich new blood vessels and the characteristics of plaque internal hemorrhage, vascular outward reconstruction and the like can be formed; the occurrence of acute cardiovascular and cerebrovascular events such as plaque rupture similar to that of the human body can be observed on the model. The method is high in model forming rate and good in repeatability, a good animal foundation is provided for medicine research and instrument consumable improvement, and a good platform is provided for exploring an atherosclerosis mechanism.

This invention relates to the use of at least one domain of ATP synthase as a lipoprotein receptor.

The invention relates to a method for preparing a colloidal gold-carbonylated cyanine-low-density lipoprotein (LDL) double-labeled probe, which is characterized in that two different tracers of colloidal gold and carbonylated cyanine (DiI) are used to label the same target protein Prepare double-labeled probes on the molecule, and use instruments and equipment to detect the functional activity of cell protein receptors. The preparation steps include: (1) extract and purify LDL; (2) prepare DiI-LDL; (3) prepare colloidal gold; (4) prepare Colloidal gold-DiI-LDL double-labeled probe; (5) Application of colloidal gold-DiI-LDL double-labeled probe. By improving the pH of the preparation environment, protein quantification and increasing the number of separations, the prepared colloidal gold-DiI-LDL double-labeled probe has the advantages of high yield, high purity, strong specificity, wide application range and rich detection methods. Laser confocal microscopy, flow cytometry and transmission electron microscopy and other instruments and equipment can accurately and efficiently detect the functional activity of cellular LDL receptors.

Feed for aquarium fish is prepared from, by mass, 20%-30% of wheat, 10%-20% of fish meal, 10%-20% of chicken liver meal, 10%-20% of silkworm chrysalis meal, 10%-20% of whole egg powder, 5%-10% of dried shrimp meal, 0.01%-1% of beta-carotene, 2%-3% of dehydrated spinach, 2%-3% of red yeast rice powder, 1%-2% of soybean petide and 0.5%-1% of 17 alpha-methyltestosterone which is purchased from Shanghai Yubo Bio-Technology Limited and is more than or equal to 98% in purity. The feed provides comprehensive and balanced nutrients for growth of the aquarium fish, and the 17 alpha-methyltestosterone activates LDL receptors on the surfaces of chromatophores at the same time, so that the lipoprotein uptake of the chromatophores is increased, the amount of carotenoid carried by lipoprotein and deposited in the chromatophores is increased, and the physical fitness and the body color of the aquarium fish are enhanced.

Substantially optically pure (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid, or a salt thereof, or a solvate thereof, which has actions of reducing amount of PCSK9 protein and increasing amount of LDL receptor.

The invention relates to a novel electrochemical luminescence kit for detecting a low-density lipoprotein receptor associated protein 4 (LRP4) antibody from a detected sample and a manufacturing method thereof. The manufactured kit comprises a streptavidin-coated magnetic bead particle working solution, a biotin-labeled LRP4 working solution, a terpyridyl ruthenium-labeled anti-human IgG antibodyworking solution, an anti-LRP4 antibody calibration product and/or quality control product working solution, a tripropylamine-containing electrochemiluminescence substrate solution and a cleaning solution. A luminescence system of the manufactured kit is electrochemiluminescence, a streptavidin-biotin biological reaction signal amplification system is used, a detection speed is high, sensitivity is high, a linear range is wide, detection result repeatability is good, and accurate quantitative detection of the anti-LRP4 antibody in a sample can be achieved.

The invention relates to a preparation method of an atherosclerotic mouse model with NOD (Non-Obese Diabetic) genetic background, and belongs to the technical fields of genetic engineering and geneticmodification. For the first time, ApoE (Apolipoprotein E) and LDLR (Low-Density Lipoprotein Receptor) genes in a NOD genetic background mouse are knocked out at the same time to obtain a gene knockout mouse model, which can induce atherosclerotic atherosclerosis, of the NOD genetic background mouse. The aorta of the atherosclerotic mouse model with the NOD genetic background has obvious atherosclerotic plaque formation. Compared with the traditional classic atherosclerotic model C57B/L6 background ApoE gene knockout mouse, the atherosclerotic mouse model has consistent incidence degree. By adopting the method disclosed by the invention, a brand new atherosclerosis gene knockout mouse model with the NOD genetic background is provided for researchers, and is of great value for the basic theoretical research as well as clinical diagnosis and treatment of atherosclerosis.

The invention relates to a tetrahydroberberine derivative and application thereof and relates to a compound represented by a formula (V) shown in the description, a preparation method therefor and application of the compound in medicine. Particularly, the invention relates to a derivative of the compound represented by the general formula (V), a preparation method for the derivative of the compound and use of the derivative of the compound in the prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, type II diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the invention can also be used for lowering total cholesterol, LDL (Low-Density Lipoprotein)-cholesterol and triglyceride, improving liver LDL receptor expression and inhibiting PCSK9 expression.

The present invention discloses a method for determining whether a compound can bind to a lipoprotein such as LDL or VLDL in a manner that lowers plasma cholesterol, the method comprising assessing the ability of the compound to form a complex with the lipoprotein such as LDL or VLDL and then determining the newly formed Does the complex cause structural changes in apoB-100 that lead to increased binding affinity for the LDL receptor. The present invention also discloses a method for lowering cholesterol in hosts, including humans. The method includes administering an effective dose of a lipoprotein capable of changing the three-dimensional structure of lipoproteins and increasing the apoB-100 protein's ability to bind LDL receptors, including receptors on the surface of liver cells. Compounds that bind to cholesterol-carrying lipoproteins (eg, LDL or VLDL) in a manner that binds to the body.

The invention discloses an adsorbent for removing blood lipoprotein and a preparation method thereof. Firstly, in the presence of an initiator, a grafting monomer is grafted on the surface of an adsorption carrier to form a connecting arm containing an aldehyde group, then the aldehyde group and Schiff base of amino acid molecules react to form a short chain containing acidic amino acids and hydrophobic amino acids, and by controlling the carrier content of acidic amino acids and hydrophobic amino acids, an LDL receptor and Apo B100-like binding domain and LDL are combined to reduce non-specific adsorption. The side chain grafting method adopted in the invention can increase a large number of binding sites and effectively load amino acids, and the side chain also functions as a connectingarm, thereby effectively reducing steric hindrance during adsorption and greatly improving the adsorption effect. The synthesis is simple and convenient, the raw materials are cheap and easily available, and thus the adsorbent has wide application prospects.

The invention relates to the technical field of traditional Chinese medicine, in particular to a blood lipid-lowering agent, which is made of the following raw materials in parts by mass: 22-28 parts of Salvia miltiorrhiza, 22-28 parts of Polygala, 18-28 parts of Snake Grape, 18- 28 servings, 18-28 servings of hanging golden lanterns, 16-24 servings of Puhuang, 16-24 servings of radish seeds, 14-20 servings of cinnamon, 14-20 servings of Ligustrum lucidum, 10-20 servings of intermittent, 5-15 servings of Polygonum cuspidatum 5-15 parts of dandelion, 5-15 parts of scallion, 5-15 parts of elm money, 5-15 parts of garcinia cambogia, 5-7 parts of kudzu root, 5-7 parts of scutellaria chinensis, 3-5 parts of fennel. The blood lipid-lowering agent of the present invention can promote the transformation of cholesterol, promote the expression of LDL receptors on cell membranes, accelerate the decomposition of lipoproteins; activate lipoprotein metabolic enzymes, promote the hydrolysis of triglycerides; and promote the metabolism of other lipids ; It can effectively remove the cholesterol deposited on blood vessels, prevent platelet aggregation, and reduce the occurrence of heart disease.

The invention belongs to the technical field of pharmacy and discloses application of nerolidol in preparing drug for treating fungal keratitis. It is put forward for the first time that nerolidol caninhibit fungus growth and has treatment effect on fungal keratitis in vivo and in vitro. In in-vivo experiments, C57BL/6 mice are adopted to build a fungal keratitis model to study impact of nerolidol on clinical scoring of model mouse cornea, neutrophil collection and human oxidized low-density lipoprotein receptor 1 and interleukin 1beta expression. In in-vitro experiments, inhibiting effect ofnerolidol at different concentrations on growth of aspergillus fumigatus is studied, and a human corneal epithelial cell model stimulated by aspergillus fumigatus is adopted to verify that nerolidolhas impact on LOX-1/IL-1beta signal pathway.

The invention provides a low-density lipoprotein receptor related gene 2 LmLRP2 of migratory locust and application of dsRNA of the gene in prevention and control of the migratory locust. The specificlow-density lipoprotein receptor related gene 2 can be silenced to kill the migratory locust. After cloning and sequencing of the low-density lipoprotein receptor related gene 2 of the migratory locust, the low-density lipoprotein receptor related gene 2 with the sequence shown as SEQ ID NO:1 is obtained; the dsRNA of the gene is designed and synthesized according to SEQ ID NO:1. After the dsRNAof the gene is injected into the body cavity of the migratory locust, the migratory locus dies before molting, during molting or after molting separately, and the permeability of the epidermis is enhanced. A new specific molecular target is provided for pest prevention and control on the basis of RNA interference, and a new approach is provided for pest prevention and control.